Company news
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news
Inovio Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 1, 2026: INOVIO to Participate in Upcoming Investor Conferences
Press releases & updates
INOVIO to Participate in Upcoming Investor Conferences
September 1, 2026
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 12, 2026
INOVIO to Report Second Quarter Financial Results on August 12, 2026
August 4, 2026
INOVIO Announces Pricing of $20.0 Million Public Offering
July 28, 2026
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
May 21, 2026
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026
INOVIO to Report First Quarter Financial Results on May 13, 2026
May 1, 2026
INOVIO Announces Pricing of $17.5 Million Public Offering
April 1, 2026
INOVIO to Participate in Upcoming Scientific Conference
April 1, 2026
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
March 12, 2026
INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
March 4, 2026
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
March 4, 2026
INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
March 4, 2026
INOVIO to Participate in Upcoming Scientific and Investor Conferences
February 12, 2026
FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
December 29, 2025
INOVIO Reports Inducement Grant Under Inducement Plan
December 19, 2025
INOVIO to Participate in December Investor Conferences
November 18, 2025
INOVIO Announces Pricing of $25 Million Public Offering
November 11, 2025
INOVIO Announces Proposed Public Offering
November 10, 2025
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 10, 2025
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
November 3, 2025
INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025
October 27, 2025
INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
October 23, 2025
Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine
October 21, 2025
INOVIO to Participate in Upcoming Scientific Conferences
September 25, 2025
INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults
August 26, 2025
INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
August 25, 2025
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 12, 2025
Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
August 11, 2025
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025
August 4, 2025
INOVIO to Present at Upcoming Scientific Conference
July 7, 2025
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
July 1, 2025
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 13, 2025
INOVIO to Present at Upcoming Scientific and Investor Conferences
April 30, 2025
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
April 29, 2025
INOVIO to Present at Upcoming Scientific Conferences
April 9, 2025
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
March 18, 2025
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
March 13, 2025
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
March 12, 2025
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
February 11, 2025
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
February 9, 2025
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
January 28, 2025
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
January 8, 2025
INOVIO Announces Pricing of $30 Million Public Offering
December 12, 2024
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
December 2, 2024
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 13, 2024
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
November 12, 2024
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
November 5, 2024
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
October 20, 2024
INOVIO Reports Inducement Grants Under Inducement Plan
October 1, 2024